HIV and syphilis testing in NYC

HIV detection depends on the assay and exposure date. CDC lists usual windows of 10–33 days for NAT and 18–45 days for a laboratory antigen/antibody test using venous blood. Rapid finger-stick antigen/antibody testing has a usual window of 18–90 days; antibody testing has a window of 23–90 days. A negative result during its window is not conclusive; repeat at the advised time. PrEP/PEP can affect the testing plan. If the exposure was within 72 hours, seek urgent PEP assessment rather than waiting for repeat testing.

Ask which rapid HIV assay the service actually offers and whether laboratory confirmation or an RNA test is needed. A rapid screen can give an early result, but the assay's exposure window still applies, and a reactive result requires confirmation. HIV and syphilis results use different interpretation pathways. For possible HIV exposure within 72 hours, seek urgent PEP assessment rather than waiting for routine results.

Yes. Syphilis is treatable, commonly with penicillin, but the regimen depends on stage, pregnancy, neurological/eye/ear involvement and treatment history. A positive antibody may remain positive after successful care, so prior records and quantitative titers matter. Obtain clinician-directed treatment, partner assessment and follow-up. New visual, hearing or neurological symptoms need prompt evaluation.

Request an HIV-testing appointment, specifying the exposure date, symptoms and whether you need screening, confirmation or prevention advice. Ask which test is being ordered and when results are expected.

Have your insurance card ready when booking. Share member details through the clinic’s confirmed secure intake process. Check with the clinic and your insurer that the exact plan covers the clinician and requested service. Ask about visit charges, any separately billed tests or medicines, and any referral or authorization requirement. Coverage and your copay or deductible depend on the plan; request a written estimate if paying yourself.

Treponemal antibodies often persist. The clinician reviews treatment records, symptoms and quantitative RPR/VDRL results to assess whether more evaluation or treatment is needed.

An RPR or VDRL can be reactive for reasons other than syphilis. Examples include some infections, autoimmune conditions, pregnancy, recent vaccinations, injecting drug use or older age. A reactive result therefore needs the treponemal confirmation pathway. If a treponemal screen is reactive but RPR is negative, the laboratory may use another treponemal test. The clinician reviews prior treatment and recent exposure. A result cannot be dismissed as false positive from one factor alone. Obtain the complete reports and a clinician’s interpretation, especially with a sore, rash, pregnancy or new eye, hearing or neurologic symptoms.

Arrange assessment now if a partner has syphilis, you have a sore or rash, or pregnancy is involved. Early syphilis can have a negative blood result, so one immediate negative may not settle a recent exposure. The clinician considers the exposure date, symptoms, prior tests and treatment. For certain previously treated people with re-exposure, a reactive treponemal result and negative RPR, CDC recommends repeat nontreponemal testing in 2–4 weeks. That is not a universal waiting rule. A known infected partner may require treatment before a new test turns positive. Do not delay symptom or partner-exposure care to reach an internet test date.

Blood collection and laboratory interpretation are separate steps. The exact service should tell you its expected turnaround for the screening test, quantitative RPR/VDRL and any confirmation. A reactive or discordant screen may require another test and review of prior treatment before the clinician can give a final interpretation. Confirm who will contact you and follow up if the promised date passes. Symptoms, pregnancy or a partner’s diagnosis may require care before the full test sequence returns.

Read the report with the clinician, including the test names, reactive/nonreactive results, quantitative RPR or VDRL titer and prior treatment records. A treponemal result can remain positive after successful treatment and does not alone prove a new infection. A reactive RPR/VDRL needs treponemal confirmation. If the tests disagree, another treponemal test and history review may be needed. Titers help follow treatment response: a fourfold change, such as 1:16 to 1:4, is meaningful when the same method is compared. RPR and VDRL numbers cannot be compared directly. The clinician combines results with symptoms and exposure history before deciding whether treatment or repeat testing is needed.